| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
HIV-IN-6 targets Src family kinases (SFK), specifically Hck, which interact with the Nef protein of HIV-Ⅰ. Nef is a viral protein that modulates host cell signaling to promote viral replication and immune evasion. By inhibiting SFK that interact with Nef, HIV-IN-6 disrupts viral replication. This mechanism makes it a potential antiviral agent for HIV research.
|
|---|---|
| ln Vitro |
In vitro, HIV-IN-6 inhibits HIV-Ⅰ viral replication by targeting Src family kinases that interact with the Nef protein. It has anti-HIV viral activity. Specific in vitro data such as IC50 values are limited in publicly available sources.
|
| ln Vivo |
In vivo studies with HIV-IN-6 are limited. As an HIV replication inhibitor, the compound has potential for antiviral research. However, specific in vivo efficacy data are not extensively documented. The compound is primarily used as a research tool for studying HIV replication and Nef function.
|
| Enzyme Assay |
In vitro kinase assays are used to characterize HIV-IN-6's inhibition of Src family kinases. Kinases including Hck are incubated with the compound and ATP substrate, and kinase activity is measured by phosphorylation of a peptide substrate. Inhibition of kinase activity is assessed. HIV replication assays are performed in virus-infected cells.
|
| Cell Assay |
Cell-based assays for HIV-IN-6 are conducted in HIV-infected cells. Cells are treated with the compound at various concentrations, and viral replication is measured by p24 antigen ELISA, qPCR, or other methods. Cytotoxicity is assessed to determine the therapeutic index.
|
| Animal Protocol |
In vivo animal experiments with HIV-IN-6 are limited. The compound could potentially be used in models of HIV infection. Specific protocols are not extensively documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of HIV-IN-6 have not been extensively characterized. The compound has molecular weight 392.43 and molecular formula C20H16N4O3S. Storage: appropriately. Specific PK parameters such as half-life, Cmax, and bioavailability have not been reported.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for HIV-IN-6 are limited. The compound is for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. The compound should be stored properly and disposed of in accordance with applicable regulations.
|
| References | |
| Additional Infomation |
HIV-IN-6 has CAS number 301357-74-4, molecular formula C20H16N4O3S, and molecular weight 392.43. It is a novel HIV-Ⅰ viral replication inhibitor targeting Src family kinases that interact with Nef. It has anti-HIV viral activity. Purity: ≥97%. Not for human use; for research purposes only.
|
| Molecular Formula |
C20H16N4O3S
|
|---|---|
| Molecular Weight |
392.43
|
| Exact Mass |
392.094
|
| CAS # |
301357-74-4
|
| PubChem CID |
2309588
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
605
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C=CC=CC=1S(=O)(NC1C(NC2C=CC=C(O)C=2)=NC2=C(C=CC=C2)N=1)=O
|
| InChi Key |
BNHZFBKIEIPSHA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16N4O3S/c25-15-8-6-7-14(13-15)21-19-20(23-18-12-5-4-11-17(18)22-19)24-28(26,27)16-9-2-1-3-10-16/h1-13,25H,(H,21,22)(H,23,24)
|
| Chemical Name |
N-[3-(3-hydroxyanilino)quinoxalin-2-yl]benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~254.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 + to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5482 mL | 12.7411 mL | 25.4823 mL | |
| 5 mM | 0.5096 mL | 2.5482 mL | 5.0965 mL | |
| 10 mM | 0.2548 mL | 1.2741 mL | 2.5482 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
